Dynamic Changes and Clinical Significance of Serum Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Patients with Cerebral Infarction_West China Medical Journal

Authors：

 LIBing , JIANGXue-song

Department of Neurology, Jiaozhou Central Hospital of Qingdao, Qingdao, Shandong 266300, P. R. China;

Corresponding?author：

Keywords：

Acute cerebral infarction; Matrix metalloproteinase-2; Matrix metalloproteinase

DOI：

10.7507/1002-0179.20150574

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the dynamic changes of the concentrations of serum matrix metalloproteinase (MMP)-2 and MMP-9, and to discuss its clinical significance. Methods From January to May 2014, 50 cases of clinically diagnosed cerebral infarction patients were included in the study as the cerebral infarction group, and we randomly selected 30 healthy volunteers at the same time in the same age group as the control group. The serum MMP-2 and MMP-9 of patients with acute cerebral infarction were detected in the onset of 24 hours, 7th day and 14th day respectively, which were compared with the control group accordingly. The patients with cerebral infarction were divided into small infarction group (1.5-3.0 cm), middle infarction group (3.1-5.0 cm) and large infarction group (>5.0 cm) according to the infraction volume. According to neurological functional deficit score they were divided into mild (0-15 points), moderate (16-30 points) and severe group (31-45 points). Changes of the level of MMP-9 and MMP-2 were compared in patients with different cerebral infarction volume and different impairment degree. Results For the cerebral infarction group, the serum MMP-2 and MMP-9 levels were significantly higher in the onset of 24 hours, 7th day and 14th day[MMP-2:(2.36±0.76), (2.86±0.87), and (2.20±0.79) ng/mL; MMP-9:(238.8±99.6), (360.4±141.8), and (152.2±80.4) ng/mL] than the control group[MMP-2:(1.20±0.27) ng/mL; MMP-9:(124.8±28.2) ng/mL] (P<0.05). The larger the infarction volume was in the patients with acute ischemic stroke, the higher the levels of serum MMP-9 and MMP-2. The severer the neurologic impairment degree was in the patients with acute ischemic stroke, the higher the levels of serum MMP-9 and MMP-2 were. Conclusion For patients with acute cerebral infarction, the levels of serum MMP-2 and MMP-9 are closely related to time of onset, infarct volume and neurological deficits, which can be used as an important basis to estimate the condition and assess the prognosis.

Citation： LIBing, JIANGXue-song. Dynamic Changes and Clinical Significance of Serum Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Patients with Cerebral Infarction. West China Medical Journal, 2015, 30(11): 2009-2012. doi: 10.7507/1002-0179.20150574 Copy

1.	Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases:structure, function, and biochemistry[J]. Circ Res, 2003, 92(8):827-839.
2.	Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis:the good, the bad, and the ugly[J]. Circ Res, 2002, 90(3):251-262.
3.	Jacob-Ferreira AL, Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species:consequences and therapeutic strategies in the heart[J]. Arch Biochem Biophys, 2013, 540(1/2):82-93.
4.	Horstmann S, Kalb P, Koziol J, et al. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients:influence of different therapies[J]. Stroke, 2003, 34(9):2165-2170.
5.	Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke[J]. Circulation, 2003, 107(4):598-603.
6.	全國第四屆腦血管病學術會議. 腦卒中患者臨床神經功能損傷程度評分標準及臨床療效評定標準[J]. 中華神經科雜志, 1996, 29(6):381-383.
7.	王新, 黃如訓, 曾進勝. 腦梗死急性期血清MMP-9的動態變化及其與腦梗死分型關系的研究[J]. 中國神經精神疾病雜志, 2005, 31(1):20-23.
8.	周進. MMP-2及MMP-9在缺血再灌注大鼠腦中的表達及意義[J]. 遼寧醫學雜志, 2005, 19(4):175-176.
9.	Akamatsu Y, Saito A, Fujimura M, et al. Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase-9 expression, and thereby attenuates ischemia/reperfusion injury in rat brain[J]. Neurosci Lett, 2011, 503(2):110-114.
10.	Brouns R, Wauters A, De Surgeloose D, et al. Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome[J]. Eur Neurol, 2011, 65(1):23-31.
11.	陳紅兵, 郭云良, 孫圣剛, 等. 大鼠腦缺血再灌流后基質金屬蛋白酶2和9的表達[J]. 解剖學雜志, 2005, 28(3):304-307.
12.	Chang DI, Hosomi N, Lucero J, et al. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia[J]. J Cereb Blood Flow Metab, 2003, 23(12):1408-1419.
13.	Magnoni S, Baker A, George SJ, et al. Differential alterations in the expression and activity of matrix metalloproteinases 2 and 9 after transient cerebral ischemia in mice[J]. Neurobiol Dis, 2004, 17(2):188-197.
14.	Guo M, Cox B, Mahale S, et al. Pre-ischemic exercise reduces matrix metalloproteinase-9 expression and ameliorates blood-brain barrier dysfunction in stroke[J]. Neuroscience, 2008, 151(2):340-351.
15.	Brouns R, Wauters A, De Surgeloose D, et al. Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome[J]. Eur Neurol, 2011, 65(1):23-31.
16.	張建平, 孟凡超, 代吉文, 等. 局部亞低溫干預對實驗大鼠腦出血后MMP-2/9表達及腦水腫的影響[J]. 中華物理醫學與康復雜志, 2007, 29(10):649-652.
17.	陶定波, 姜秀麗, 雷陽, 等. 急性期腦梗死患者血清MMP-9水平動態變化意義及與預后的關系[J]. 中風與神經疾病雜志, 2009, 26(2):176-179.
18.	陶晶, 李志, 劉卉萍. 急性腦梗死患者血清基質金屬蛋白酶-9檢測的臨床意義[J]. 實用醫技雜志, 2011, 18(12):1243-1245.

1. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases:structure, function, and biochemistry[J]. Circ Res, 2003, 92(8):827-839.
2. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis:the good, the bad, and the ugly[J]. Circ Res, 2002, 90(3):251-262.
3. Jacob-Ferreira AL, Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species:consequences and therapeutic strategies in the heart[J]. Arch Biochem Biophys, 2013, 540(1/2):82-93.
4. Horstmann S, Kalb P, Koziol J, et al. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients:influence of different therapies[J]. Stroke, 2003, 34(9):2165-2170.
5. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke[J]. Circulation, 2003, 107(4):598-603.
6. 全國第四屆腦血管病學術會議. 腦卒中患者臨床神經功能損傷程度評分標準及臨床療效評定標準[J]. 中華神經科雜志, 1996, 29(6):381-383.
7. 王新, 黃如訓, 曾進勝. 腦梗死急性期血清MMP-9的動態變化及其與腦梗死分型關系的研究[J]. 中國神經精神疾病雜志, 2005, 31(1):20-23.
8. 周進. MMP-2及MMP-9在缺血再灌注大鼠腦中的表達及意義[J]. 遼寧醫學雜志, 2005, 19(4):175-176.
9. Akamatsu Y, Saito A, Fujimura M, et al. Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase-9 expression, and thereby attenuates ischemia/reperfusion injury in rat brain[J]. Neurosci Lett, 2011, 503(2):110-114.
10. Brouns R, Wauters A, De Surgeloose D, et al. Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome[J]. Eur Neurol, 2011, 65(1):23-31.
11. 陳紅兵, 郭云良, 孫圣剛, 等. 大鼠腦缺血再灌流后基質金屬蛋白酶2和9的表達[J]. 解剖學雜志, 2005, 28(3):304-307.
12. Chang DI, Hosomi N, Lucero J, et al. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia[J]. J Cereb Blood Flow Metab, 2003, 23(12):1408-1419.
13. Magnoni S, Baker A, George SJ, et al. Differential alterations in the expression and activity of matrix metalloproteinases 2 and 9 after transient cerebral ischemia in mice[J]. Neurobiol Dis, 2004, 17(2):188-197.
14. Guo M, Cox B, Mahale S, et al. Pre-ischemic exercise reduces matrix metalloproteinase-9 expression and ameliorates blood-brain barrier dysfunction in stroke[J]. Neuroscience, 2008, 151(2):340-351.
15. Brouns R, Wauters A, De Surgeloose D, et al. Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome[J]. Eur Neurol, 2011, 65(1):23-31.
16. 張建平, 孟凡超, 代吉文, 等. 局部亞低溫干預對實驗大鼠腦出血后MMP-2/9表達及腦水腫的影響[J]. 中華物理醫學與康復雜志, 2007, 29(10):649-652.
17. 陶定波, 姜秀麗, 雷陽, 等. 急性期腦梗死患者血清MMP-9水平動態變化意義及與預后的關系[J]. 中風與神經疾病雜志, 2009, 26(2):176-179.
18. 陶晶, 李志, 劉卉萍. 急性腦梗死患者血清基質金屬蛋白酶-9檢測的臨床意義[J]. 實用醫技雜志, 2011, 18(12):1243-1245.

West China Medical Journal

Dynamic Changes and Clinical Significance of Serum Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Patients with Cerebral Infarction

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content